NCT03049852View on ClinicalTrials.gov

Safety and Efficacy of CBT-001 Ophthalmic Solution in Patients With Pterygium

PHASE2CompletedINTERVENTIONAL
Enrollment

75

Participants

Timeline

Start Date

April 15, 2017

Primary Completion Date

April 30, 2018

Study Completion Date

April 30, 2018

Conditions
Pterygium
Interventions
DRUG

CBT-001 single dose

One drop in the study administered one time

DRUG

Vehicle

One drop in the study administered three times daily (TID) for 4 weeks

DRUG

CBT-001 Multi-dose

One drop in the study administered three times daily (TID) for 4 weeks

Trial Locations (1)

92651

Harvard Eye Associates, Laguna Beach

Sponsors
All Listed Sponsors
lead

Cloudbreak Therapeutics, LLC

INDUSTRY